Celator Pharma Reports Results Showing Reduced Healthcare Resource Use with VYXEOSTM Compared to Standard Treatment for AML

Celator Pharmaceuticals, Inc.

today announced that patients treated in a Phase 2 clinical study with VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) with newly diagnosed AML demonstrated reduced healthcare resource use compared to conventional chemotherapy known as 7+3. These results were presented at the AMCP Managed Care & Specialty Pharmacy Annual Meeting in San Francisco, CA, April 19-22, 2016. The presentation, titled "VYXEOS™ (CPX-351) increases event-free survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care," was based on data from a clinical study directed by Jeffrey E. Lancet, M.D., senior member and chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center. Researchers evaluated treatment details and healthcare resource use in the context of clinical outcomes, such as treatment response and event-free survival (EFS). VYXEOS treated patients had; a longer EFS, with a median of 197 days compared to 60 days with 7+3, a slightly longer time in the hospital, median of 38 days compared to 35 days. The majority of patients on the VYEXOS arm with hospital stays >60 days also experienced a response (75%) with many having one or more risk factors, a higher ratio of median EFS days to median hospital days, with a ratio of 5.2 compared to 1.7, which means the time spent out of the hospital was longer for the patients treated with VYXEOS, fewer hospital admissions, median of 1 admission with VYXEOS compared to 2 admissions with 7+3, a higher rate of remission after one induction cycle (42/56 vs. 15/21; p=0.03), and received consolidation treatment more frequently as outpatients (15/37 vs. 2/15; p=0.02). High risk, including secondary, AML patients treated with VYXEOS also had longer EFS and a favorable ratio of EFS days to hospital days. "This is the first time we have evaluated the impact of VYXEOS on hospital resource use in relation to its established clinical benefit," said Dr. Lancet. "Although, we did see longer hospital stays in VYXEOS treated patients, some of those costs are clearly offset by fewer hospital admissions and outpatient consolidation treatments in this group. This study suggests significant value that VYXEOS could provide for patients, providers and payers over the course of the disease." The poster will be available on Celator's website (www.celatorpharma.com).